Interpreting Positive Results from Cardiac Genetic Testing (CNE)

Genetic testing for cardiac diseases allows healthcare providers to move beyond a one-size-fits-all approach and adopt a more personalized and targeted management strategy, resulting in improved patient outcomes and quality of life. However, it is essential to interpret genetic test results accurately and in the context of the patient's clinical presentation, family history, and other relevant factors. In this course, you will practice interpreting positive genetic test results to personalize patient management for cardiac disease. This course is part of a series, Implementing Cardiogenomics in Clinical Practice.

To claim credit, follow the steps in the learning path.

CNE Information and Disclosures 

Jointly Provided by The Jackson Laboratory and Northwestern University Feinberg School of Medicine Office of Continuing Medical Education.

Release Date: November 9, 2023 
Expiration Date: January 27, 2025  

Target Audience  
This activity is designed to meet the educational needs of practicing nurses and advanced practice nurses. 

Learning Outcome
Identify and manage individuals at increased genetic risk of cardiovascular disease due to familial factors and hereditary cardiac syndromes.  

CNE Approval Statement 
This nursing continuing professional development activity was approved by the Northeast Multistate Division Education Unit, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. 

Nurses are eligible for a maximum of .5 contact hours upon the completion of this activity.

Planners, Writer, Reviewers

• Lisa Castillo, MS, CGC - Northwestern University
• Kristen DeBerg, MS, CGC - Sanford Health
• Emily Edelman, MS, CGC - The Jackson Laboratory
• Mary Maradik, MSN, RN - Northwestern University
• Therese Ingram, MA - The Jackson Laboratory
• Kalisi Logan, MS, CGC - The Jackson Laboratory
• Laura Rasmussen-Torvik, PhD, MPH - Northwestern University
• Greg Webster, MD, MPH - Northwestern University

Conflict of Interest Disclosure 
This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest. Unless otherwise noted, the program planners and faculty do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this course. 

The following disclosures are reported that could be perceived as a real or apparent conflict of interest in the education program: Emily Edelman received salary support from Pfizer Inc. through an unrestricted quality improvement grant that focuses on improving ascertainment of hereditary breast cancer, provided by the American Community Cancer Centers and Pfizer Independent Grants for Learning & Change. Kalisi Logan served on the Scientific Advisory Board for Igentify. In their roles as planners and content authors, Ms. Edelman and Ms. Logan recused themselves from all deliberations relating to content related to the commercial entity with which they have financial interest and were not responsible for reviewing for bias any related content. All educational material has been peer-reviewed by external reviewers to assess for bias. 

Commercial Support  
This program was supported by educational grants from the American Heart Association. There is no commercial support being received for this activity.   

References 

Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. Oct 2018;15(10):e190-e252.

Guo L, Torii S, Fernandez R, et al. Genetic Variants Associated With Unexplained Sudden Cardiac Death in Adult White and African American Individuals. JAMA Cardiol. Sep 1 2021;6(9):1013-1022.

Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. Oct 2 2018;138(14):1387-1398. doi:10.1161/CIRCULATIONAHA.117.033200

Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. Nov 2021;23(11):2029-2037. 

Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. Aug 2023;25(8):100866. 

Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Dec 22 2020;76(25):e159-e240.

Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm. Nov 2019;16(11):e373-e407.

van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. Jan 31 2012;59(5):493-500.

Hardware/Software Requirements

Audio speakers or headphones 

Screen resolution of 800X600 or higher 
Adobe Reader 5.0 or higher 

Check the supported browsers. 

Should you have questions about CME approval, contact the Feinberg School of Medicine Office of Continuing Medical Education.

Disclaimer 

All information in Implementing Cardiogenomics in Clinical Practice is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Implementing Cardiogenomics in Clinical Practice. Reliance on any information in Implementing Cardiogenomics in Clinical Practice is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Implementing Cardiogenomics in Clinical Practice.